DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 115 filers reported holding DENALI THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $1,801,000 | +73.8% | 40,370 | +96.6% | 0.20% | +83.0% |
| Q3 2021 | $1,036,000 | -66.0% | 20,529 | -47.1% | 0.11% | -70.1% |
| Q2 2021 | $3,047,000 | -52.3% | 38,839 | -65.3% | 0.38% | -60.9% |
| Q1 2021 | $6,391,000 | -55.6% | 111,919 | -34.9% | 0.96% | -44.5% |
| Q4 2020 | $14,410,000 | +124.1% | 172,040 | -4.1% | 1.73% | +86.4% |
| Q3 2020 | $6,429,000 | +47.3% | 179,429 | -0.6% | 0.93% | +12.4% |
| Q2 2020 | $4,364,000 | +53.3% | 180,498 | +11.1% | 0.82% | +25.6% |
| Q1 2020 | $2,846,000 | +145.6% | 162,522 | +144.2% | 0.66% | +238.1% |
| Q4 2019 | $1,159,000 | +9.9% | 66,557 | -3.4% | 0.19% | -26.2% |
| Q3 2019 | $1,055,000 | -27.9% | 68,864 | -2.4% | 0.26% | -22.9% |
| Q2 2019 | $1,464,000 | -10.6% | 70,532 | 0.0% | 0.34% | -5.8% |
| Q1 2019 | $1,638,000 | +298.5% | 70,532 | +254.4% | 0.36% | +226.1% |
| Q4 2018 | $411,000 | – | 19,900 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |